GLP-1 medications and pregnancy: what the evidence actually shows

These drugs are widely used for diabetes and weight management. If you are pregnant or planning to be, here is what the evidence shows, where the gaps are, and what to bring to your next appointment. This article is editorial health information for general audiences, not individualized medical advice. For questions about your own medications or pregnancy, contact a qualified healthcare provider. , -

GLP-1 receptor agonists, including semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, Saxenda), are not recommended during pregnancy. Current product labeling advises stopping these medications at least two months before trying to conceive. That guidance reflects a precautionary stance based on animal study data and a genuine absence of human safety information beyond the first trimester. The human data that do exist are cautiously reassuring for early accidental exposure, but they are limited. "Not alarming so far" is not the same as "proven safe." This article explains what the evidence shows, where it runs out, and what questions are worth raising with your care team.

Several distinct concerns drive the current guidance, and it helps to understand them separately. Animal study findings Reproductive toxicity studies in animals have shown fetal malformations and other adverse outcomes at doses comparable to human therapeutic doses for both liraglutide and semaglutide. Animal-to-human translation is imperfect, and the species and doses used in these studies matter. Even so, findings of this kind carry regulatory weight, particularly when human data are scarce. The placenta question GLP-1 receptor agonists are large molecules. Based on their size and pharmacology, they are not expected to cross the placenta significantly during the first trimester. That said, "not expected to cross significantly" does not mean fetal exposure is zero, and there are essentially no data on what happens in the second or third trimester. The absence of evidence is not evidence of absence. Weight loss during pregnancy is separately contraindicated This point is sometimes overlooked. GLP-1 medications promote weight loss, and intentional weight loss during pregnancy is associated with small-for-gestational-age infants and related complications. This concern exists independently of any direct drug toxicity. Even if a GLP-1 medication were otherwise harmless, its weight-loss effect would still be a problem during pregnancy. Regulatory status These medications are not licensed for use during pregnancy in any major market. Their use in pregnancy is considered off-label.

The human evidence available so far is more reassuring than the animal data, but it comes with significant caveats. Studies involving more than 1,000 women with first-trimester GLP-1 receptor agonist exposure have not found an increased rate of major birth defects compared to baseline population risk. Large cohort data also suggest that GLP-1 RA exposure in people with pre-gestational type 2 diabetes does not increase congenital malformation risk beyond what is already elevated in that population, with rates appearing comparable to those seen with insulin. These findings are meaningful. They suggest that accidental first-trimester exposure, which is common given that many pregnancies are unplanned, does not appear to carry a dramatically elevated risk of birth defects. Several limitations deserve plain acknowledgment. Nearly all human data cover only the first trimester. Safety in the second and third trimesters is essentially unstudied in humans. Observational studies cannot fully control for confounders. Disease severity, other medications, and lifestyle factors all vary between groups and are difficult to account for completely. "No increased risk detected" is not the same as "proven safe." These are different statements, and conflating them does patients a disservice. Long-term developmental outcomes in children exposed in utero are unknown. Follow-up data are sparse. A small number of case reports describe normal early development, but no large, long-term studies exist.

Semaglutide and liraglutide have long half-lives. After the last dose, drug levels persist in the body for weeks. This is why current labeling recommends stopping at least two months before attempting to conceive, not simply stopping when a pregnancy test comes back positive. The practical reality is that many pregnancies are unplanned. Some people will have first-trimester exposure before they know they are pregnant. This is a common scenario, not a rare edge case, and the available human data are relevant precisely because of it. Stopping a GLP-1 medication before pregnancy also comes with tradeoffs worth acknowledging honestly. Discontinuation may lead to weight regain, which can be clinically significant for people managing obesity or type 2 diabetes. It is worth discussing with a provider well before conception is attempted, so that a management plan is in place before the medication stops.

People with pre-gestational type 2 diabetes face elevated baseline risks for congenital malformations regardless of which medication they take. Good blood sugar control before and during pregnancy is critical, and that control needs to be maintained through the transition off a GLP-1 medication. Insulin is the standard of care for managing diabetes during pregnancy. GLP-1 receptor agonists are not a substitute for insulin in this context. The fact that cohort studies show comparable malformation rates between GLP-1 RA users and insulin users is informative, but it does not change current clinical guidance. Gestational diabetes, which is diagnosed during pregnancy rather than before it, is a separate condition. GLP-1 receptor agonists are not used to treat it.

Some uncertainty in medicine reflects incomplete research rather than a known danger. The following gaps are real, and patients deserve to know about them. Second- and third-trimester safety. There are no meaningful human data here. This is the most significant gap in the current evidence base. Long-term outcomes in exposed children. No large studies have followed children with in-utero GLP-1 RA exposure through childhood or beyond. Neurodevelopmental and metabolic outcomes are unknown. Anti-drug antibodies. Some people taking semaglutide develop antibodies to the drug. Whether these antibodies affect pregnancy outcomes has not been characterized. Signals in observational data. Some observational studies have suggested associations between GLP-1 RA exposure and outcomes such as preterm delivery or altered gestational weight gain. Whether these reflect drug effects or underlying disease is not yet clear. Applicability to weight-management populations. Most human pregnancy data come from people with type 2 diabetes. How those findings apply to people taking GLP-1 medications solely for weight management is not well established.

The following are questions worth raising with your provider, not recommendations for what to do. If you are currently taking a GLP-1 medication and thinking about pregnancy, ask about a preconception timeline and what stopping looks like for your specific situation, including how your diabetes or weight will be managed after discontinuation. If you became pregnant while taking one of these medications, let your provider know as soon as possible. Ask them to review your exposure timing and discuss whether any additional monitoring is appropriate. Based on current data, accidental first-trimester exposure does not appear to carry a dramatically elevated risk of birth defects, but your provider should be aware and can help you interpret what the evidence means for your situation. If you have type 2 diabetes and are planning pregnancy, ask about transitioning to insulin and optimizing blood sugar control before conception. This matters independently of GLP-1 use and is one of the most important steps you can take. If you are managing obesity and concerned about weight regain after stopping, ask about evidence-based nutrition and lifestyle support during pregnancy. Weight loss during pregnancy is not the goal, but there are strategies for managing weight in ways that support both your health and your baby's. Ask your provider about pregnancy registries or pharmacovigilance programs. Reporting medication exposure during pregnancy helps build the evidence base that will eventually answer the questions that remain open today.

The current recommendation is clear: GLP-1 receptor agonists should be stopped before pregnancy, ideally at least two months before trying to conceive. The human evidence so far is cautiously reassuring for first-trimester accidental exposure. Data for later pregnancy simply do not exist, and research is ongoing. Guidance will likely be updated as more evidence accumulates, particularly on second- and third-trimester exposure and long-term child outcomes. If you are taking a GLP-1 medication and pregnancy is part of your plans, talking with your care team before conception, rather than after, is the most useful next step.